Matritech Establishes Medical Advisory Board For NMP66 Blood Test for Detection of Breast Cancer

Board to assist in preparation of clinical trial



Apr 17, 2001, 01:00 ET from Matritech, Inc.

    NEWTON, Mass., April 17 /PRNewswire/ -- Matritech, Inc.(Nasdaq:   NMPS), a
 cancer diagnosis company, announced today that it has established a Breast
 Cancer Medical Advisory Board to provide clinical input on the development of
 the company's NMP66(TM) blood test for the detection of breast cancer.
     Last year, Matritech reported proof of clinical concept results for NMP66
 in the detection of breast cancer. Using Matritech's proprietary specimen
 preparation and mass spectrometry procedures, NMP66 was found in every one of
 45 samples from women with invasive breast cancer, and was absent in all
 "normal" specimens.
 
     The Breast Cancer Medical Advisory Board is composed of five members:
 
     --V. Suzanne Klimberg, M.D., Director of the Breast Cancer Program and
       Chief of the Division of Breast Surgical Oncology at the Arkansas Cancer
       Research Center, and Director of the Women's Oncology Service at the
       John L. McClellan Memorial VA Hospital, Little Rock, AK. Dr. Klimberg
       also serves on the Executive Council of the Society of Surgical
       Oncologists.
     --John W. Smith II, M.D., Chief of Clinical Research, Robert W. Franz
       Cancer Research Center, Earle A. Chiles Research Institute, at the
       Providence Portland Medical Center, Portland, OR. Dr. Smith also serves
       on the working group of the Breast Committees of the National Surgical
       Adjuvant Breast and Bowel Project (NSABP) and Southwest Oncology Groups
       (SWOG).
     --Diana Lueftner Dr. Med., Coordinator of the Breast Cancer Biochemical
       Marker Study Group, Universitaetsklinikum Charite, Berlin, Germany. The
       Charite Hospital is the largest university hospital in Europe. Dr.
       Lueftner will also coordinate clinical trial activities for NMP66 at
       affiliated teaching hospitals in Germany.
     --Rache Simmons, M.D., Strang Weill Cornell Breast Center, the New York
       Presbyterian Hospital, Weill Medical College of Cornell University, New
       York, NY. Dr. Simmons is a former president of the American Society of
       Breast Surgeons, and continues to serve on its board.
     --Avi Ben-Ora, M.D., Founder of Ben-Ora Imaging, a facility for screening
       and diagnostic mammography, ultrasound and biopsy of breast disease. Dr.
       Ben-Ora formerly served as the President of the Arizona division of the
       American Cancer Society. He is currently a consultant in managed care
       and medico-legal issues in mammography.
 
     "Almost half the women in this country who should be getting annual
 mammograms do not, and over 40,000 women will die from breast cancer this year
 in the United States alone," said Stephen D. Chubb, Chairman and Chief
 Executive Officer of Matritech. "The formation of this advisory board marks an
 important step in Matritech's drive to provide a blood based breast cancer
 test. These clinicians fight breast disease on a daily basis and their
 expertise and frontline patient experience will help us in our goal to produce
 a test that will play a significant role in detecting breast cancer early
 enough to be treated successfully."
    "We value the perspective brought to the NMP66 project by some of the
 leading experts in the management of women with breast cancer," said David L.
 Corbet, President and Chief Operating Officer of Matritech. "Included on the
 Medical Advisory Board are specialists in surgery, oncology and radiology;
 internationally recognized experts in diagnosis and treatment of breast
 cancer; professionals from academic institutions and private practice; and,
 participants in federally funded clinical research projects like the STAR
 (Study of Tamoxifen and Raloxifene) trial.
 
     "The establishment of the Advisory Board will assist Matritech in
 beginning  our first clinical trial of the NMP66 test, which is a very high
 priority for Matritech. NMP66 is the first of a new generation  of cancer
 detection tests based on our mass spectrometry techniques," added Corbet.
     Matritech's nuclear matrix protein (NMP) core technology correlates levels
 of NMPs in body fluids to the presence of cancer. Multiple published clinical
 studies have validated this ability of NMPs to detect early stage cancerous
 abnormalities. Matritech has a pipeline of NMP-based products in development
 for the detection of major cancers including bladder, cervical, breast, colon
 and prostate cancers. The NMP22 Test Kit is cleared for marketing in the
 United States for management and screening of individuals at risk of bladder
 cancer. It also is sold in China, Europe and Japan where it is approved for
 bladder cancer screening.
 
     Matritech, Inc., based in Newton, Mass., is using its NMP technology,
 discovered at the Massachusetts Institute of Technology and licensed
 exclusively to Matritech, to develop and commercialize innovative serum-,
 cell- and urine-based NMP diagnostics that enable physicians to reliably
 detect and monitor the presence of bladder, cervical, breast, colon and
 prostate cancers.
 
     Statements Under the Private Securities Litigation Reform Act
 Any forward looking statements related to the Company's expectations regarding
 the performance, market acceptance, future sales and regulatory approvals of
 the Company's NMP66 test for breast cancer are subject to a number of risks
 and uncertainties, many of which are beyond the Company's control. These
 include, but are not limited to, risks related to the Company's limited
 capital resources, unforeseen delays in or denials of FDA and other regulatory
 approvals, future product demand and pricing, performance of distributors,
 competitive products and technical developments, health care reform and
 general business and economic conditions. There can be no assurances that the
 Company's expectations for its products will be achieved.
 
      Stephen D. Chubb, CEO
      David L. Corbet, President
      Matritech, Inc.
      617-928-0820
 
      Derek Caldwell
      Investor Relations
      Sunrise Financial Group
      212-421-1616
 
      Jon Siegal
      Media Relations
      Ronald Trahan Associates, Inc.
      508-647-9782, ext. 15
 
 

SOURCE Matritech, Inc.
    NEWTON, Mass., April 17 /PRNewswire/ -- Matritech, Inc.(Nasdaq:   NMPS), a
 cancer diagnosis company, announced today that it has established a Breast
 Cancer Medical Advisory Board to provide clinical input on the development of
 the company's NMP66(TM) blood test for the detection of breast cancer.
     Last year, Matritech reported proof of clinical concept results for NMP66
 in the detection of breast cancer. Using Matritech's proprietary specimen
 preparation and mass spectrometry procedures, NMP66 was found in every one of
 45 samples from women with invasive breast cancer, and was absent in all
 "normal" specimens.
 
     The Breast Cancer Medical Advisory Board is composed of five members:
 
     --V. Suzanne Klimberg, M.D., Director of the Breast Cancer Program and
       Chief of the Division of Breast Surgical Oncology at the Arkansas Cancer
       Research Center, and Director of the Women's Oncology Service at the
       John L. McClellan Memorial VA Hospital, Little Rock, AK. Dr. Klimberg
       also serves on the Executive Council of the Society of Surgical
       Oncologists.
     --John W. Smith II, M.D., Chief of Clinical Research, Robert W. Franz
       Cancer Research Center, Earle A. Chiles Research Institute, at the
       Providence Portland Medical Center, Portland, OR. Dr. Smith also serves
       on the working group of the Breast Committees of the National Surgical
       Adjuvant Breast and Bowel Project (NSABP) and Southwest Oncology Groups
       (SWOG).
     --Diana Lueftner Dr. Med., Coordinator of the Breast Cancer Biochemical
       Marker Study Group, Universitaetsklinikum Charite, Berlin, Germany. The
       Charite Hospital is the largest university hospital in Europe. Dr.
       Lueftner will also coordinate clinical trial activities for NMP66 at
       affiliated teaching hospitals in Germany.
     --Rache Simmons, M.D., Strang Weill Cornell Breast Center, the New York
       Presbyterian Hospital, Weill Medical College of Cornell University, New
       York, NY. Dr. Simmons is a former president of the American Society of
       Breast Surgeons, and continues to serve on its board.
     --Avi Ben-Ora, M.D., Founder of Ben-Ora Imaging, a facility for screening
       and diagnostic mammography, ultrasound and biopsy of breast disease. Dr.
       Ben-Ora formerly served as the President of the Arizona division of the
       American Cancer Society. He is currently a consultant in managed care
       and medico-legal issues in mammography.
 
     "Almost half the women in this country who should be getting annual
 mammograms do not, and over 40,000 women will die from breast cancer this year
 in the United States alone," said Stephen D. Chubb, Chairman and Chief
 Executive Officer of Matritech. "The formation of this advisory board marks an
 important step in Matritech's drive to provide a blood based breast cancer
 test. These clinicians fight breast disease on a daily basis and their
 expertise and frontline patient experience will help us in our goal to produce
 a test that will play a significant role in detecting breast cancer early
 enough to be treated successfully."
    "We value the perspective brought to the NMP66 project by some of the
 leading experts in the management of women with breast cancer," said David L.
 Corbet, President and Chief Operating Officer of Matritech. "Included on the
 Medical Advisory Board are specialists in surgery, oncology and radiology;
 internationally recognized experts in diagnosis and treatment of breast
 cancer; professionals from academic institutions and private practice; and,
 participants in federally funded clinical research projects like the STAR
 (Study of Tamoxifen and Raloxifene) trial.
 
     "The establishment of the Advisory Board will assist Matritech in
 beginning  our first clinical trial of the NMP66 test, which is a very high
 priority for Matritech. NMP66 is the first of a new generation  of cancer
 detection tests based on our mass spectrometry techniques," added Corbet.
     Matritech's nuclear matrix protein (NMP) core technology correlates levels
 of NMPs in body fluids to the presence of cancer. Multiple published clinical
 studies have validated this ability of NMPs to detect early stage cancerous
 abnormalities. Matritech has a pipeline of NMP-based products in development
 for the detection of major cancers including bladder, cervical, breast, colon
 and prostate cancers. The NMP22 Test Kit is cleared for marketing in the
 United States for management and screening of individuals at risk of bladder
 cancer. It also is sold in China, Europe and Japan where it is approved for
 bladder cancer screening.
 
     Matritech, Inc., based in Newton, Mass., is using its NMP technology,
 discovered at the Massachusetts Institute of Technology and licensed
 exclusively to Matritech, to develop and commercialize innovative serum-,
 cell- and urine-based NMP diagnostics that enable physicians to reliably
 detect and monitor the presence of bladder, cervical, breast, colon and
 prostate cancers.
 
     Statements Under the Private Securities Litigation Reform Act
 Any forward looking statements related to the Company's expectations regarding
 the performance, market acceptance, future sales and regulatory approvals of
 the Company's NMP66 test for breast cancer are subject to a number of risks
 and uncertainties, many of which are beyond the Company's control. These
 include, but are not limited to, risks related to the Company's limited
 capital resources, unforeseen delays in or denials of FDA and other regulatory
 approvals, future product demand and pricing, performance of distributors,
 competitive products and technical developments, health care reform and
 general business and economic conditions. There can be no assurances that the
 Company's expectations for its products will be achieved.
 
      Stephen D. Chubb, CEO
      David L. Corbet, President
      Matritech, Inc.
      617-928-0820
 
      Derek Caldwell
      Investor Relations
      Sunrise Financial Group
      212-421-1616
 
      Jon Siegal
      Media Relations
      Ronald Trahan Associates, Inc.
      508-647-9782, ext. 15
 
 SOURCE  Matritech, Inc.